CN115916245A - 用于治疗晚发型庞贝病的组合物和方法 - Google Patents

用于治疗晚发型庞贝病的组合物和方法 Download PDF

Info

Publication number
CN115916245A
CN115916245A CN202180041026.9A CN202180041026A CN115916245A CN 115916245 A CN115916245 A CN 115916245A CN 202180041026 A CN202180041026 A CN 202180041026A CN 115916245 A CN115916245 A CN 115916245A
Authority
CN
China
Prior art keywords
treatment
increase
pharmaceutical composition
weeks
score
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180041026.9A
Other languages
English (en)
Chinese (zh)
Inventor
P·芬恩
A·哈米德
K·安哈克
C·威尔逊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of CN115916245A publication Critical patent/CN115916245A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/0102—Alpha-glucosidase (3.2.1.20)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN202180041026.9A 2020-06-14 2021-06-11 用于治疗晚发型庞贝病的组合物和方法 Pending CN115916245A (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202063038857P 2020-06-14 2020-06-14
US63/038,857 2020-06-14
US202063076037P 2020-09-09 2020-09-09
US63/076,037 2020-09-09
US202163147629P 2021-02-09 2021-02-09
US63/147,629 2021-02-09
US202163157490P 2021-03-05 2021-03-05
US63/157,490 2021-03-05
PCT/US2021/037111 WO2021257409A1 (en) 2020-06-14 2021-06-11 Compositions and methods for treating late-onset pompe disease

Publications (1)

Publication Number Publication Date
CN115916245A true CN115916245A (zh) 2023-04-04

Family

ID=76797137

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180041026.9A Pending CN115916245A (zh) 2020-06-14 2021-06-11 用于治疗晚发型庞贝病的组合物和方法

Country Status (13)

Country Link
US (2) US12533396B2 (enExample)
EP (1) EP4164678A1 (enExample)
JP (2) JP2023530112A (enExample)
KR (1) KR20230025874A (enExample)
CN (1) CN115916245A (enExample)
AU (1) AU2021293021A1 (enExample)
BR (1) BR112022025314A2 (enExample)
CA (1) CA3182409A1 (enExample)
IL (1) IL299015A (enExample)
MX (1) MX2022016019A (enExample)
TW (1) TW202214302A (enExample)
WO (1) WO2021257409A1 (enExample)
ZA (1) ZA202300544B (enExample)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103432566A (zh) * 2008-12-16 2013-12-11 建新公司 寡糖-蛋白缀合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723296B2 (en) 2001-01-18 2010-05-25 Genzyme Corporation Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
JP5137814B2 (ja) 2005-04-06 2013-02-06 ジェンザイム・コーポレーション 治療ターゲティングのための酸不安定リンカーを介するｐｅｇおよびポリシアルリソソーム酵素のコンジュゲート
CN102978185B (zh) 2007-01-18 2015-02-11 建新公司 包含氨基氧基基团的寡糖及其轭合物
US8883979B2 (en) 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
IL299470B2 (en) 2015-12-30 2026-05-01 Amicus Therapeutics Inc Improved acid alpha-glucosidase for the treatment of Pompe disease
CA3019354A1 (en) 2016-03-30 2017-10-05 Amicus Therapeutics, Inc. Method for selection of high m6p recombinant proteins
KR102618519B1 (ko) 2016-03-30 2023-12-28 아미쿠스 세라퓨틱스, 인코포레이티드 재조합 산 알파-글루코시다제를 포함하는 제형
EP4100120A1 (en) 2020-02-08 2022-12-14 Genzyme Corporation Compositions and methods for treating pompe disease

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103432566A (zh) * 2008-12-16 2013-12-11 建新公司 寡糖-蛋白缀合物

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DIMACHKIE ET AL.: "NEO1 and NEO-EXT studies: Long-term safety and exploratory efficacy of repeat avalglucosidase alfa dosing for 5.5 years in lateonset Pompe disease patients", MOLECULAR GENETICS AND METABOLISM, 31 January 2020 (2020-01-31) *
PENA ET AL.: "NEO1 and NEO-EXT studies: Long-term safety of repeat avalglucosidase alfa dosing for 4.5 years in late-onset Pompe disease patients", MOLECULAR GENETICS AND METABOLISM, 31 December 2019 (2019-12-31) *
PENA ET AL.: "Safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of the novel enzyme replacement therapy avalglucosidase alfa (neoGAA) in treatment-naïve and alglucosidase alfa-treated patients with late-onset Pompe disease: A phase 1, open-label, multicenter, multinational, ascend", NEUROMUSCULAR DISORDERS, vol. 29, 31 December 2019 (2019-12-31), pages 167 - 186 *
STRAUB ET AL.: "792 - COMET Methodology: Comparison of the Efficacy and Safety of the Enzyme Replacement Therapies, NeoGAA and Alglucosidase alfa, in Treatment-Naïve Patients With Late-Onset Pompe Disease", JOURNAL OF INBORN ERRORS OF METABOLISM AND SCREENING, vol. 5, 1 January 2017 (2017-01-01) *

Also Published As

Publication number Publication date
WO2021257409A1 (en) 2021-12-23
US12533396B2 (en) 2026-01-27
US20230256062A1 (en) 2023-08-17
EP4164678A1 (en) 2023-04-19
JP2026117025A (ja) 2026-07-14
IL299015A (en) 2023-02-01
KR20230025874A (ko) 2023-02-23
BR112022025314A2 (pt) 2023-01-03
AU2021293021A1 (en) 2023-02-23
MX2022016019A (es) 2023-04-10
TW202214302A (zh) 2022-04-16
JP2023530112A (ja) 2023-07-13
CA3182409A1 (en) 2021-12-23
US20260216302A1 (en) 2026-07-30
ZA202300544B (en) 2026-02-25

Similar Documents

Publication Publication Date Title
US20250018050A1 (en) Dosing of muscle targeting complexes for treating dystrophinopathies
JP7193476B2 (ja) 組換えヒト酸性アルファグリコシダーゼ
US20240279323A1 (en) Methods for the treatment of scleroderma and related conditions
WO2020163480A1 (en) Recombinant human acid alpha-glucosidase and uses thereof
EP3815696A1 (en) Composition comprising antisense oligonucleotide and use thereof for treatment of duchenne muscular dystrophy
KR20250021401A (ko) 척수 근위축증을 치료하기 위한 마이오스타틴 저해제의 용도
AU2020341135A1 (en) Treatment of liver disease or disorder comprising ActRII receptor antagonists
Namsolleck et al. LP2, the first lanthipeptide GPCR agonist in a human pharmacokinetics and safety study
US20170128520A1 (en) Treatment of autoimmune and/or inflammatory disease using novel caveolin modulators
US20240327831A1 (en) Compositions comprising exon skipping oligonucleotide conjugates for treating muscular dystrophy
RU2861586C2 (ru) Композиции и способы лечения болезни помпе с поздним началом
US12533396B2 (en) Compositions and methods for treating late-onset Pompe disease
CN110381987A (zh) 使用稳定化α-半乳糖苷酶治疗法布里病的治疗方法
US12251430B2 (en) Compositions and methods for treating Pompe disease
US20110044987A1 (en) Monoclonal antibodies and binding fragments thereof directed to the melanocortin-4 receptor and their use in the treatment of cachexia and related conditions and diseases
EP4230196A1 (en) Compounds for use in the treatment of dystrophinopathies
JP2025540119A (ja) 小児患者の遅発型ポンペ病の治療方法
CA3252291A1 (en) METHODS OF TREATMENT FOR POMPE DISEASE
RU2850019C1 (ru) Композиции и способы для лечения болезни помпе
Flanigan et al. Initial Experience From the INSPIRE DUCHENNE Phase 1/2 Study of SGT-003 Microdystrophin Gene Therapy for Duchenne Muscular Dystrophy
US20240166710A1 (en) Methods of administering long-acting growth hormone polypeptides
WO2026058194A1 (en) Polypeptide dosage regimens
EP4330393A1 (en) Products and methods for inducing exon 2 skipping of the dmd gene in treating muscular dystrophy
TW202535919A (zh) 類升糖素肽2(glp-2)類似物之調配物及其用途
HK40032702A (en) Recombinant human acid alpha-glucosidase

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination